BioCentury
ARTICLE | Company News

WuXi, ABL expand deal to develop bispecifics

March 1, 2019 7:31 PM UTC

WuXi Biologics Inc. (HKSE:2269) granted ABL Bio Inc. (KOSDAQ:298380) rights to use WuXi's WuXiBody and CD3 platforms to develop and commercialize bispecific antibodies targeting an undisclosed immune checkpoint receptor.

The partners said the deal expands an exclusive November license granting ABL rights to the platforms to develop and manufacture multiple other bispecific antibodies...

BCIQ Company Profiles

ABL Bio Inc.

WuXi Biologics Inc.